Summit Street Capital Management’s Medifast MED Stock Holding History

Summit Street Capital Management’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-29,500	Closed	-$1.13M	–	31
2024 Q1	$1.13M	Hold	29,500	–	–	0.43%	31
2023 Q4	$1.98M	Sell	29,500 -29,645	-50%	-$2.07M	0.84%	30
2023 Q3	$4.43M	Hold	59,145	–	–	1.98%	27
2023 Q2	$5.45M	Buy	59,145 +4,810	+9%	+$428K	2.57%	24
2023 Q1	$5.63M	Buy	54,335 +28,642	+111%	+$3.17M	2.99%	19
2022 Q4	$2.96M	Buy	25,693 +9,337	+57%	+$1.09M	1.87%	26
2022 Q3	$1.77M	Hold	16,356	–	–	1.23%	29
2022 Q2	$2.95M	Hold	16,356	–	–	1.94%	27
2022 Q1	$2.79M	Hold	16,356	–	–	1.69%	26
2021 Q4	$3.42M	Hold	16,356	–	–	2.14%	22
2021 Q3	$3.15M	Hold	16,356	–	–	2.09%	24
2021 Q2	$4.63M	Hold	16,356	–	–	2.96%	17
2021 Q1	$3.46M	Hold	16,356	–	–	2.25%	22
2020 Q4	$3.21M	Hold	16,356	–	–	2.4%	20
2020 Q3	$2.69M	Sell	16,356 -25,337	-61%	-$4.17M	2.38%	20
2020 Q2	$5.79M	Buy	41,693 +4,071	+11%	+$374K	4.85%	2
2020 Q1	$2.35M	Buy	+37,622	New	+$3.43M	2.54%	19

Other funds holding MED

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Summit Street Capital Management's MED Position: Q2 2024 in Review

Summit Street Capital Management sold out of Medifast (MED) in Q2 2024, closing a stake of 29,500 shares — an estimated $1.13M sold.

Summit Street Capital Management first reported a position in MED in Q1 2020 and held it in 17 quarters. The position peaked at $5.79M in Q2 2020. 158 funds tracked by Wall St. Rank hold MED as of Q2 2024.

Summit Street Capital Management reported no remaining Medifast position as of Q2 2024 after selling out during the quarter.
Summit Street Capital Management sold 29,500 Medifast shares in Q2 2024, an estimated $1.13M.
Summit Street Capital Management first reported a position in Medifast in Q1 2020 and held it in 17 quarters.
Summit Street Capital Management's Medifast position peaked at $5.79M in Q2 2020.
158 funds tracked by Wall St. Rank held Medifast as of Q2 2024.

Based on Summit Street Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.